Head & Neck Cancer

Latest News

HPV Testing, p16 IHC May be Needed for Oropharyngeal Cancer Trials | Image Credit: © CLIPAREA.com - stock.adobe.com.
HPV Testing, p16 IHC May be Needed for Oropharyngeal Cancer Trials

March 22nd 2023

Human papillomavirus and p16 discordance may correlate with a worse prognosis for oropharyngeal cancer, according to data from an individual patient data analysis.

Camrelizumab plus apatinib demonstrate impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.
Camrelizumab Yields ‘Impressive’ Activity in Head & Neck Cancer Subtype

March 7th 2023

Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem for radiotherapy-induced severe oral mucositis in those with head and neck cancer.
FDA Grants Priority Review to Avasopasem for Treatment-Related Oral Mucositis

February 15th 2023

Findings from a randomized clinical trial suggest that tele-cognitive behavioral therapy may help reduce body image distress among survivors of head and neck cancer.
Tele-Cognitive Therapy May Improve Body Image Distress in Head and Neck Cancer Survivors

February 1st 2023

The biologic license application for toripalimab plus chemotherapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma is expected to be resubmitted by mid-summer 2023.
FDA Issues Complete Response Letter to Toripalimab BLA in Metastatic Nasopharyngeal Carcinoma

January 3rd 2023

Video Interviews

More News